Physician profile
William C Sullivan
NPI 1427018381
$3,934.08
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $719 · 2020: $95.55 · 2021: $902 · 2022: $944 · 2023: $601 · 2024: $673.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,274.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,273.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $732.16 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $643.68 | 2019-2024 | |
| Abbvie INC. | $541.14 | 2021-2024 | Dalvance |
| Janssen Pharmaceuticals, INC | $393.97 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $279.02 | 2020-2024 | Lokelma, Farxiga |
| Merck Sharp & Dohme LLC | $268.29 | 2019-2024 | Zerbaxa, Dificid, Recarbrio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $204.64 | 2019-2023 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Otsuka America Pharmaceutical, INC. | $180.67 | 2019 | |
| Gilead Sciences, INC. | $149.64 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $117.59 | 2019-2023 | Camzyos |
| Alexion Pharmaceuticals, INC. | $92.65 | 2019-2024 | Ultomiris |
| Novo Nordisk INC | $70.55 | 2023-2024 | Ozempic, Rybelsus |
| Boston Scientific Corporation | $66.91 | 2019-2022 | |
| Paratek Pharmaceuticals, INC. | $55.61 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.40 | 2022-2024 | Xifaxan |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $27.02 | 2021-2022 | |
| Cmp Pharma, INC. | $24.04 | 2021 | |
| Ucb, INC. | $18.09 | 2024 | Briviact |
| Melinta Therapeutics, LLC | $13.61 | 2021 | |
| Electromed, INC. | $13.40 | 2023 | Smartvest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Sullivan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.